Navigation Links
Acacia Pharma Raises £15 Million ($23.5 Million) to Advance Clinical Development of Lead Products for Supportive Care
Date:9/3/2013

CAMBRIDGE, England, September 3, 2013 /PRNewswire/ --

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised £15 million (~$23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S. Current investors Gilde Healthcare and Lundbeckfond Ventures also participated in the round. Dr Alex Pasteur of Fidelity Biosciences and Dr Martin Edwards of Novo A/S have joined the Board of Acacia Pharma as Non-executive Directors.

Acacia Pharma will use the proceeds to:

  • complete Phase III development of APD421 for the prevention of post-operative nausea & vomiting (PONV);
  • complete Phase II development of APD403 for the prevention of chemotherapy induced nausea & vomiting (CINV); and
  • develop the commercial presentation of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients.

"I am delighted to welcome Fidelity and Novo to the Company and would like to thank Gilde and Lundbeckfond for their continued support," commented Dr Julian Gilbert, Acacia Pharma's CEO. "The Company is about to initiate a number of key studies with results being available in 2014. The data generated to date in PONV, CINV and xerostomia have been excellent; therefore we look forward to continued success."

Dr Alex Pasteur of Fidelity Biosciences added, "Significant numbers of post-surgical patients do not receive adequate nausea and vomiting prophylaxis. APD421, Acacia Pharma's lead product, a D2/D3 antagonist, showed excellent efficacy in its Phase II trial, and had a very good safety profile. We believe that a drug with this novel mechanism and displaying these characteristics can provide a major contribution
'/>"/>

SOURCE Acacia Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. 6th BSMA Annual Executive Summit to Address the Supply Chain Challenges and Solutions of Biopharma
2. Before the Bell Scans: Hologic Inc., St. Jude Medical Inc., ResMed Inc., and Navidea Biopharmaceuticals Inc.
3. BIOPHARMA Executives Summit, 6th BSMA Annual Conference: Look Who Is Confirmed to Speak
4. EnduRx Pharmaceuticals to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
5. Rational Design of Modified Release Dosage Forms: From Pharmacokinetic Targets Through Technology Selection, new life science webinar hosted by Xtalks
6. New Book Provides Industry Guidance for Major Pharmaceutical Firms
7. HealthCare, Technology Briefing: Market Movers for the Week - Technologies-Scan Corp, GNC, Galena Biopharma, Immunomedics, Amarin
8. Pharma Contract Manufacturing, Research & Packaging Market a New Report Available at ReportsnReports.com
9. Cambridge Semantics to Present on Smart Data and Competitive Intelligence Informatics at 2013 Pharma CI Conference & Exposition
10. Pharmaceutical and Food Product Safety Made Easier with the Environmental Wireless Validation System by Deadline Solutions, Inc
11. FDAs Lawrence Yu to Participate in Live Video Chat on Question-Based Review (QbR) for Generics on CPhI Pharma Evolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 LayerBio is an ... and wound care. The National Eye Institute (NEI) at ... a Phase I SBIR grant to develop a drug-eluting ... the most common cause of vision loss in people ... worldwide. According to Dr. Ken Mandell, LayerBio’s Founder and ...
(Date:12/19/2014)... Boston, MA (PRWEB) December 18, 2014 ... software, announced the appointment of Siri Bryant as the ... the new Director of Core Implementations. These two new ... provide outstanding customer service by ensuring that iLab continues ... , “In the last four years, iLab has been ...
(Date:12/19/2014)... With only 2 weeks left of ... Sartorius Biohit products . The product specials include Buy ... Pipette Trade-in Program, and free pipette tips. , Sartorius ... the world. They are ideal for lab technicians performing ... ,     Full volume range of 0.1 uL to ...
(Date:12/19/2014)... 2014   ISN has released its third ... publication series. With data aggregated from over ... 2013 within its online contractor management platform, ISNetworld, this ... indicator (KPI) statistics. The ... publication is available in two industry specific volumes: ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3
... , QUINCY, Mass., Dec. 7 Myriant ... developer and manufacturer of renewable biochemicals, has been selected by ... $50 million for its planned biobased Succinic Acid facility in ... won funding or loan guarantees, Myriant was the only award ...
... , , Response Rate Increases to 41% ... All Evaluable Patients , QUEBEC CITY, Dec. 7 /PRNewswire-FirstCall/ - ... "Company"), a global biopharmaceutical company focused on endocrine therapy and ... ( KERX) reported updated efficacy and safety data as well ...
... , ... customizing, manufacturing, and marketing enzymes for the,chemical industry, announced today ... CEO of the Company. Going forward, EUCODIS Bioscience,sole focus will ... experience in commercial enzyme development and,on its proven technology of ...
Cached Biology Technology:Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2
(Date:11/21/2014)... 2014 C-Labs LLC, a leading provider of ... (IoT), today announced the appointment of John Traynor ... a strategic advisor to the firm, Mr. Traynor will ... is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. Photo ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... could release at least one billion Euro in cash ... The claim has been made following an international study ... companies in monetary terms. Entitled Sustainable Value Creation by ... European research team including academics from Queen,s University Management ...
... FEBRUARY 23, 2010 Scientists seeking answers to the complex ... receptors triggers preterm labor, study how genetics and the ... D can suppress factors that make some women more ... support of the March of Dimes. The March ...
... Researchers at the University of Illinois at Chicago Institute ... federal grant to determine whether or not TV food advertising ... project, funded by the National Cancer Institute, is unique because ... the amount of time that children watch TV. "A ...
Cached Biology News:Study highlights sustainable footprint of chemical companies 2Study highlights sustainable footprint of chemical companies 3March of Dimes provides $2.6 million in new funding for preterm birth research 2Do TV ads affect children's diet, obesity? 2
Rad51, N-terminal...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
... Extraction Reagent extracts cytosolic proteins ... while preserving their phosphorylation state. ... the CytoBuster Protein Extraction reagent, ... is compatible with Western blotting, ...
Biology Products: